Last reviewed · How we verify
Ranexa
At a glance
| Generic name | Ranexa |
|---|---|
| Also known as | Ranolazine |
| Sponsor | Midwest Cardiovascular Research Foundation |
| Target | Multidrug resistance protein 1, Potassium voltage-gated channel subfamily H member 2, Sodium channel protein type 5 subunit alpha |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
- Angina pectoris
Common side effects
- Dizziness
- Headache
- Constipation
- Nausea
- Bradycardia
- Palpitations
- Tinnitus
- Vertigo
- Blurred vision
- Abdominal pain
- Dry mouth
- Vomiting
Serious adverse events
- Renal failure
- Angioedema
- Pulmonary fibrosis
- Pancytopenia
- Thrombocytopenia
- Leukopenia
- Eosinophilia
- Hypotension
- Orthostatic hypotension
- Hyperhidrosis
Key clinical trials
- Inhibition of Late Sodium Current (INa) to Prevent Coronary MICROvascular Dysfunction in Patients Presenting With ST-Elevation Myocardial Infarction and Multivessel Disease: INaMICRON Study (PHASE2, PHASE3)
- A Study of Ranolazine in ALS (PHASE2)
- Feasibility Trial for a Right Ventricular Failure Platform Trial (PHASE2)
- Bioequivalence Study of Ranolazine Extended-release Tablets in Healthy Chinese Subjects (PHASE1)
- Reduce Crohn's-Associated Diarrhea With Sodium Channel Therapy (PHASE2)
- Ranolazine in Ischemic Cardiomyopathy (PHASE4)
- Safety and Efficacy of Ranolazine for the Treatment of Amyotrophic Lateral Sclerosis (PHASE2)
- Impact of Ranolazine on Coronary Microcirculatory Resistance (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |